We are live on
!
Find out more
CCM
Camber Capital Management Portfolio holdings
AUM
$1.07B
1-Year Est. Return
8.19%
This Fund
S&P 500
This Quarter
Est. Return
+23.73%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$2.85B
AUM Growth
+$953M
(+50%)
Cap. Flow
+$552M
Cap. Flow
% of AUM
19.37%
Top 10 Holdings %
Top 10 Hldgs %
57.93%
Holding
41
New
6
Increased
9
Reduced
8
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
WBA
Walgreens Boots Alliance
WBA
|
+$116M |
| 2 |
GSK
GSK
|
+$112M |
| 3 |
Tenet Healthcare
THC
|
+$64.5M |
| 4 |
Biogen
BIIB
|
+$51.6M |
| 5 |
Universal Health Services
UHS
|
+$31.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cigna
CI
|
+$42.4M |
| 2 |
AMAG
AMAG Pharmaceuticals
AMAG
|
+$41.3M |
| 3 |
CHNG
Change Healthcare Inc. Common Stock
CHNG
|
+$32.9M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
+$30.4M |
| 5 |
Atara Biotherapeutics
ATRA
|
+$18.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 75.16% |
| 2 | Technology | 8.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CHNG
1
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| $242M | 8.51% |
13,000,000
-2,000,000
| -13% | -$32.9M |
|
2
Viatris
VTRS
$20.7B
| $225M | 7.89% |
12,000,000
| – | – |
|
|
3
Universal Health Services
UHS
$9.88B
| $193M | 6.76% |
1,400,000
+250,000
| +22% | +$31.1M |
|
|
ALXN
4
DELISTED
Alexion Pharmaceuticals
ALXN
| $184M | 6.44% |
1,175,000
-125,000
| -10% | -$16.1M |
|
5
CALL
Gilead Sciences
GILD
$163B
| $146M | 5.11% |
+2,500,000
| New | +$151M |
|
6
HCA Healthcare
HCA
$85.7B
| $140M | 4.91% |
850,000
+125,000
| +17% | +$18.3M |
|
7
Alkermes
ALKS
$8.39B
| $135M | 4.73% |
6,750,000
-500,000
| -7% | -$9.15M |
|
8
Perrigo
PRGO
$1.43B
| $134M | 4.71% |
3,000,000
+150,000
| +5% | +$6.95M |
|
|
9
GSK
GSK
$104B
| $129M | 4.52% |
2,800,000
+2,440,000
| +678% | +$112M |
|
10
CALL
Bristol-Myers Squibb
BMY
$132B
| $124M | 4.35% |
+2,000,000
| New | +$123M |
|
|
11
Tenet Healthcare
THC
$21.8B
| $120M | 4.2% |
3,000,000
+2,000,000
| +200% | +$64.5M |
|
|
WBA
12
DELISTED
Walgreens Boots Alliance
WBA
| $120M | 4.2% |
+3,000,000
| New | +$116M |
|
13
CALL
AbbVie
ABBV
$455B
| $107M | 3.76% |
+1,000,000
| New | +$96.1M |
|
14
Myriad Genetics
MYGN
$507M
| $98.9M | 3.47% |
5,000,000
| – | – |
|
15
Bausch Health
BHC
$2.25B
| $88.4M | 3.1% |
4,250,000
-250,000
| -6% | -$4.66M |
|
16
Ironwood Pharmaceuticals
IRWD
$614M
| $85.4M | 3% |
7,500,000
+250,000
| +3% | +$2.74M |
|
17
Sarepta Therapeutics
SRPT
$1.64B
| $68.2M | 2.39% |
400,000
-25,000
| -6% | -$3.7M |
|
18
Brookdale Senior Living
BKD
$3.49B
| $54M | 1.9% |
12,200,000
-2,800,000
| -19% | -$10.3M |
|
|
19
Biogen
BIIB
$30.7B
| $49M | 1.72% |
+200,000
| New | +$51.6M |
|
|
TECX
20
Tectonic Therapeutic
TECX
$538M
| $43.7M | 1.53% |
261,111
+111,111
| +74% | +$19.8M |
|
21
Teva Pharmaceuticals
TEVA
$41.2B
| $43.4M | 1.52% |
4,500,000
| – | – |
|
22
Nektar Therapeutics
NKTR
$2.41B
| $42.5M | 1.49% |
166,667
| – | – |
|
23
Collegium Pharmaceutical
COLL
$1.17B
| $40.1M | 1.41% |
2,000,000
| – | – |
|
|
WBA
24
CALL
DELISTED
Walgreens Boots Alliance
WBA
| $39.9M | 1.4% |
+1,000,000
| New | +$38.7M |
|
25
Coherus Oncology
CHRS
$227M
| $38.2M | 1.34% |
2,200,000
| – | – |
|
Similar funds
PP
SAF
NRD
FC
GIM
SC
BWA
CCP
Camber Capital Management's Q4 2020 Portfolio in Review
As of Q4 2020, Camber Capital Management held 41 positions worth $2.85B, up 50% from $1.9B the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Camber Capital Management deployed $552M of net new capital in Q4 2020, opening 6 new positions and adding to 9 existing holdings. Its largest new stake was Walgreens Boots Alliance: 3,000,000 shares worth $120M.
By sector, the portfolio is most concentrated in Healthcare at 75% of assets, down from 82% a quarter earlier, followed by Technology.
On the sell side, the largest reduction was Change Healthcare Inc. Common Stock, an estimated $32.9M trimmed.
- Camber Capital Management's largest Q4 2020 buy was Walgreens Boots Alliance: 3,000,000 shares worth $120M.
- Camber Capital Management added most to GSK in Q4 2020, an estimated $112M increase.
- Camber Capital Management's biggest Q4 2020 reduction was Change Healthcare Inc. Common Stock, cutting an estimated $32.9M.
- Camber Capital Management fully exited Cigna in Q4 2020, selling an estimated $42.4M.
- Camber Capital Management's ten largest holdings make up 58% of its $2.85B portfolio in Q4 2020.
- Camber Capital Management opened 6 new positions and closed 9 in Q4 2020.
- Camber Capital Management's portfolio value rose 50% quarter-over-quarter to $2.85B.
Based on Camber Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.